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Abstract
Nitrates have been a major part of the internist’s pharmacopoeia for more than 100 years, predominantly for the relief of
anginal symptoms. The effects of nitroglycerin on the eye and specifically on intraocular pressure has been investigated with
diverse results. However, nitroglycerin may also serve to protect retinal ganglion cells against glutamate mediated toxicity—a
form of cell death that may be critical in glaucomatous blindness. Consequently, we therefore sought to evaluate whether
nitroglycerin preparations, taken for non-ophthalmic reasons, had an effect on glaucomatous damage. © 1998 Elsevier Science
Ltd. All rights reserved.
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1. Introduction
Glaucoma is a disease that is generally characterized
by a slow, chronic, progressive optic neuropathy in the
presence of an elevated intraocular pressure [1]. Histo-
logically, the optic neuropathy seen in glaucoma is due
to the loss of retinal ganglion cells and the degeneration
of their axons [1]. The chronic nature of this disease is
suggestive of a low level of insult with a cumulative
deleterious effect on retinal ganglion cells. Theories
regarding the pathogenesis of optic nerve damage in
primary open angle glaucoma fall into two broad cate-
gories, mechanical and ischemic. Pressure-mediated
damage of the optic nerve is hypothesized to be the
result of either a direct mechanical effect (trauma hy-
pothesis) or by a compromise of the vasculature (is-
chemia hypothesis). These insults may damage axons at
the lamina cribrosa with subsequent death of the retinal
ganglion cells. Current therapy for most forms of glau-
coma is directed at lowering the intraocular pressure in
an attempt to interrupt or abort the sequence of events
that putatively result in death of retinal ganglion cells.
Nitrates have been a major part of the internist’s
pharmacopoeia for more than 100 years, predominantly
for the relief of anginal symptoms [2]. In 1915, Wessely
first reported that the administration of amyl nitrite led
to an increase in intraocular pressure (IOP) in the cat
[3]. Since this initial report, the effects of nitroglycerin
in patients with glaucoma have received much attention
with inconclusive results [4–8]. Various investigators
have reported that nitrates have deleterious, salubrious
or no effect on glaucoma patients. Wizemann and
Wizemann reported that a short course of organic
nitrates led to a drop in IOP [9]. Hessemer and Schmidt
found a minimal drop in IOP with oral nitrates, but did
find significant declines in ocular perfusion pressures,
raising concerns about possible vascular compromise
[10]. Nathanson and colleagues have demonstrated that
topical nitroglycerin can lower IOP in glaucoma pa-
tients, probably because of the ability of nitroglycerin
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and related compounds to activate guanylate cyclase
and thereby modulate IOP [11,12].
However, nitroglycerin may also serve to protect
retinal ganglion cells against glutamate mediated toxic-
ity—a form of cell death that we have suggested may
be critical in glaucomatous blindness. Nearly four
decades ago, Lucas and Newhouse demonstrated that a
single subcutaneous injection of glutamate into young
mice resulted in selective damage to the retinal ganglion
cell layer [13]. Glutamate can cause an optic nerve
degeneration that is identical to that seen in glaucoma
[14].
We and others have shown that the concentration of
glutamate in glaucomatous vitreous is potentially toxic
to retinal ganglion cells [15–17]. Glutamate toxicity is
predominantly mediated through activation of the N-
methyl-D-aspartate (NMDA) subtype of glutamate re-
ceptor. If glutamate is indeed part of the
pathophysiology of the neuronal loss in glaucoma, then
agents that perturb the N-methyl-D-aspartate receptor
might affect the course of the disease.
Multiple pharmacological sites on the N-methyl-D-
aspartate receptor modulate its activity [18]. The redox
modulatory site consists of multiple thiol (or sulfhydryl)
groups forming one or more disulfide bonds on the
receptor [19]. This site is of particular interest since it
acts as a ‘gain’ control for current flux through NMDA
receptor-operated channels and can affect neurotoxicity
produced by excessive NMDA receptor activation
[20,21]. Reducing agents enhance the activity of the
NMDA receptor; oxidizing agents can form disulfide
bonds from vicinal or paired free thiol groups and
decrease NMDA receptor function and block neurotox-
icity [22].
Nitroglycerin (NTG) and other drugs that generate
nitric oxide (NO) can down-regulate NMDA receptor
function by oxidizing this redox modulatory site
[23,24]. These common nitrovasodilator drugs may,
under certain circumstances, ameliorate NMDA recep-
tor-mediated neurotoxicity [23,22].
Inasmuch that we have suggested that glutamate may
play a role in the visual loss seen in glaucoma [15],
nitroglycerin is an excellent candidate drug for limiting
such glutamate mediated damage in the retina. Nitro-
glycerin can modulate the NMDA receptor via NO-re-
lated species [23,22]. Given these data and hypotheses
in toto, we therefore sought to evaluate whether nitro-
glycerin preparations, taken for non-ophthalmic rea-
sons, had an effect on the rate of glaucomatous
damage.
2. Materials and methods
A total of 60 patients of the Glaucoma Consultation
Service at the Massachusetts Eye and Ear Infirmary
were retrospectively identified who met the following
inclusion criteria: (1) a diagnosis of hypertensive open
angle glaucoma with an elevated IOP (\21 mm Hg on
at least one visit), no evidence of pseudoexfoliative
changes, transillumination defects, or Krukenberg spin-
dle, a gonioscopic report of open angles and evidence
of optic neuropathy consistent with glaucoma; (2) a
history of taking one of several long-acting nitroglyc-
erin preparations (isordil, nitropaste or nitropatch) for
an 8 year period and (3) the availability of at least two
sets of both optic nerve stereo photographs and visual
field examinations over the same 8 year period. The
initial entry date into the study was defined by presen-
tation to the Glaucoma Consultation Service, when
patients underwent both optic nerve photographs and
visual field examinations. It is not possible to establish
how many patients had previously been accurately di-
agnosed with glaucoma before presentation. Patients
were excluded if they were not continuously on nitrates
throughout the 8 year period (medication histories were
evaluated at each visit). Patients with low tension glau-
coma were excluded, as were those who were only
taking sublingual nitroglycerin.
A total of 60 patients were identified who had not
taken nitrates during a similar period. These patients
were matched for age, the presence or absence of visual
field loss on presentation and diagnosis with open angle
glaucoma. Intraocular pressures and medication histo-
ries were recorded for all patients.
Optic nerve changes indicative of glaucoma included
the presence of optic nerve asymmetry (i.e. a difference
of more than 0.2 in cup-to-disc ratios between the two
eyes), evidence of progressive enlargement of the optic
cup, notching of the nerve rim, vertical elongation of
the cup, splinter hemorrhage, or nasal displacement of
the vessels [25]. Visual fields were performed on either
the Goldmann or Humphrey perimeters. Minimal reli-
ability criteria for the Humphrey visual fields were
B20% fixation losses, or B33% false negatives or
positives. Any visual field test that did not meet these
criteria was not included and the first subsequent ac-
ceptable visual field utilized. Goldmann visual field
defects were to the III4e stimulus or greater and were
larger than 5°. Humphrey visual field defects encom-
passed three adjacent test stimuli and were 5 dB or
greater. One eye (selected at random) was evaluated for
each patient. Visual fields and optic nerve photographs
were analyzed in a masked fashion by two examiners.
The investigators were masked as to whether the pa-
tients were taking systemic nitrates or not. Deteriora-
tion was defined as deepening or enlarging of a
scotoma, or the identification of a new area of visual
field loss (as defined above). Optic nerve deterioration
was defined as any evidence of glaucomatous change in
the contour, vasculature, or depth of the cup. Each set
of photographs and visual fields were analyzed twice. If
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any three evaluations were considered as indicating
deterioration, the patient was said to have progressed.
Each patient could only be scored as having progressed
once for either visual field or optic nerve.
3. Statistical analysis
Demographic characteristics were compared between
the two groups using a two-sample Student’s t-test for
continuous data or Fisher’s exact test for proportional
data. The kappa statistic was used to measure interob-
server agreement [26]. Multiple logistic regression was
performed to analyze response data for each binary end
point: optic nerve deterioration and visual field deterio-
ration. The likelihood ratio chi-square test was used to
assess the significance of nitrates after controlling for
intraocular pressure in the model [27]. Kaplan–Meier
survival curves were compared between the two groups
using the log-rank test to assess the time-related effects
of treatment [28]. Cox’s proportional hazards model
was used to analyze time to either optic nerve or visual
field deterioration by simultaneously adjusting for IOP
as a covariate and testing for significance of treatment
in the multivariate model [29]. Log hazards ratios and
standard errors were estimated and were used to calcu-
late confidence intervals on the hazards ratio with lower
confidence limits]1.25 to indicate whether nitrates
were significantly superior to control in reducing the
risk of optic nerve or visual field deterioration. Addi-
tional analyses were performed to assess the effects of
optic nerve deterioration as a potential risk factor for
visual field deterioration and to evaluate whether IOP
was a risk factor for each end point. Two-tailed values
of PB0.05 were considered significant throughout.
Data analysis was conducted with the SPSS statistical
package, version 6.1 (SPSS, Chicago, IL).
4. Results
Intraobserver and interobserver reliabilities were
both excellent (K\0.90). Control and patients receiv-
ing nitrates were well-matched for age, sex and race.
Patient demographics are summarized in Table 1. Pa-
tients receiving nitrates were slightly but not signifi-
cantly older than control patients (P0.08). There
were no differences in the distribution of males and
females between the two groups (P0.58) and no
difference in the distribution of race (P0.24). Both
groups had similar proportions of patients receiving
intraocular surgery (P0.64), although more control
patients received laser surgery (35% versus 13%, PB
0.01). The mean (9S.D.) intraocular pressures (aver-
aged IOP measurements for all visits during the 8-year
period) for the control and nitrate groups were 18.09
2.6 and 17.392.8 mm Hg, respectively (P0.15).
Logistic regression analysis established that optic
nerve deterioration and visual field deterioration was
significantly lower in the nitrate group (PB0.0001 and
P0.02, respectively). Deterioration of the optic nerve
occurred in 24 control patients (40%) and 15 nitrate
patients (25%). The mean time (9S.E.) to optic nerve
deterioration of 7594 and 8493 months for control
and treatment groups, respectively (PB0.05, log-rank
test). The Kaplan–Meier plot in Fig. 1 shows a slower
rate of optic nerve deterioration for the nitrate group
over time.
Deterioration of the visual field occurred in 17 con-
trol patients (28.3%) and 9 nitrate patients (15%). Mean
time (9S.E.) to visual field deterioration was 8393
and 9392 months for control and treatment groups,
respectively (P0.05, log-rank test). The Kaplan–
Meier survival curves for visual field deterioration are
presented in Fig. 2. The log-rank test suggests that
treatment may retard the rate of visual field deteriora-
tion, however this effect is brought out more strongly in
the multivariate analysis. Specifically, by simulta-
neously controlling for IOP in the Cox proportional
hazards model, the monthly risk was about 20 times
lower for optic nerve deterioration and four times lower
for visual field deterioration among nitrate patients.
The estimated optic nerve deterioration hazards ratio
for control versus treatment was 19.88 (95% confidence
interval, 7.60–52.08, PB0.0001). Similarly, the visual
field deterioration hazards ratio was estimated at 4.21
(95% CI, 1.75–10.09, P0.001).
A total of 19 of the 39 patients (48.7%) who had
optic nerve deterioration compared to only seven of the
81 patients without optic nerve deterioration (8.6%)
had visual field deterioration (PB0.0001). Logistic re-
gression estimated a 10-fold increase in the odds of
visual field deterioration for patients with compared to





77.598.7 74.798.6Age in years, mean9S.D
Sex, no. (%)
34 (56.7)Female 38 (63.3)
Male 22 (36.7)26 (43.3)
Race, no. (%)
8 (13.3)African American 14 (23.3)
White 52 (86.7) 46 (76.7)
18.092.6 17.392.8IOP (mm Hg), mean9S.D.
Surgery, no. (%)
8 (13.3)Laser 8 (13.3)
Intraocular 7 (11.7) 7 (11.7)
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Fig. 1. Kaplan–Meier survival curves for optic nerve deterioration comparing nitrate and control groups. A statistically significant difference was
observed (log-rank test, PB0.05) indicating a faster rate of optic nerve deterioration in the control group.
10.04, 95% CI3.97–24.85). Moreover, visual field
deterioration occurred significantly faster among pa-
tients with compared to those without optic nerve
deterioration (mean time (9SE), 7294 month versus
9491 month, PB0.0001, log-rank test).
5. Discussion
These results support the surprising conclusion that
the concurrent administration of nitrates for non-glau-
comatous reasons is beneficial in terms of retarding
both visual field loss and glaucomatous optic neuropa-
thy. There are several flaws inherent in our study,
however, that cannot be overlooked. First and fore-
most, we were not able to control adequately for the
‘cardiac’ health of our nitrate population. Those pa-
tients in the nitrate group were presumably in poorer
cardiac health, at least with respect to anginal symp-
toms. This may induce a confounding variable as well
with respect to compliance—patients who are taking
nitrate preparations to avoid anginal symptoms may be
more compliant with all medications. These two issues
can only be addressed by the prospective administra-
tion of nitrates to a glaucomatous population without
cardiac compromise. That is beyond the scope of this
study.
The predicted findings: (1) that optic nerve and visual
field deterioration were correlated and (2) that intraoc-
ular pressure was predictive of both, supports the
methodology employed in this study.
Putting these caveats aside, however, there are sev-
eral explanations to account for the potential beneficial
effects of nitrates on the glaucomatous eye. Systemic
nitrates may have an effect on the intraocular pressure.
Although our analysis does not support this hypothesis,
our sample size may not suffice to uncover it. Although
we found no significant difference in overall intraocular
pressure, nitrates may induce a lower pressure in the
diurnal cycle that is not detectable by routine clinical
tonometry. Alternatively, the chronic use of nitrates
may have a beneficial effect on the optic nerve vascula-
ture. In collaboration with Grunwald and DuPont we
have found that patients receiving long term nitrate
therapy have larger retinal vessels than controls [30].
Chronic glutamate mediated ganglion cell excitotoxic
damage may play a role in glaucomatous optic neu-
ropathy [15–17]. Animals maintained on chronic nitro-
glycerin preparations are resistant to such an
excitotoxic challenge [31]. Consequently, nitrate prepa-
rations may be directly neuroprotective, rendering reti-
nal ganglion cells more resistant to the toxic effects of
the glaucomatous process. Chronic nitrate therapy—
through its ability to downregulate sensitivity to gluta-
mate—may protect retinal ganglion cells against
glaucoma associated excitotoxicity.
Regardless of mechanism of action, our data suggest
that concomitant use of systemic nitrates in glaucoma
patients may offer a protective effect against glaucoma-
tous optic neuropathy. Given the inherent flaws in our
retrospective study, a prospective study may provide
further information. It may be more appropriate for
additional retrospective data to be collected first. How-
ever, it is potentially intriguing that agents known to
perturb the N-methyl-D-aspartate subtype of glutamate
receptor also retard glaucomatous damage.
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Fig. 2. Kaplan–Meier survival curves for visual field deterioration comparing nitrate and control groups. Univariate analysis suggested that visual
field deterioration was faster for control patients (log-rank test, P0.05). The effect of nitrates on retarding the rate of visual field deterioration
was more evident in the multivariate Cox regression model when simultaneously controlling for intraocular pressure (PB0.0001).
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